Table 5.
Functioning and familial burden for epilepsy
| Program (n = 71) | Control (n = 20) | ANCOVA | Full cohort (n = 91) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | (SD) | Mean | (SD) | Effect size F, partial eta2 |
P-val* | Mean | (SD) | Effect size Z, r |
P-val** | |
| WHODAS | 0.72, < 0.01 | 0.40 | 6.38, 0.67 | < 0.0001 | ||||||
| Baseline | 35.6 | (20.9) | 25.8 | (21.3) | 33.5 | (21.3) | ||||
| end point | 10.2 | (21.1) | 12.8 | (25.7) | 10.8 | (22.1) | ||||
| Δ score | − 25.4 | (28.4) | − 13.1 | (21.7) | − 22.7 | (27.4) | ||||
| BAS | < 0.01, < 0.01 | 0.98 | 8.09, 0.85 | < 0.0001 | ||||||
| Baseline | 73.0 | (7.9) | 69.1 | (9.0) | 72.1 | (8.3) | ||||
| end point | 58.4 | (6.6) | 57.6 | (6.4) | 58.2 | 6.5 | ||||
| Δ score | − 14.6 | (9.0) | − 11.5 | (8.6) | − 13.9 | (8.9) | ||||
WHODAS World Health Organization Disability Assessment Schedule 2.0 Short Version, BAS burden assessment schedule
* P-value taken from ANCOVA (analysis of covariance) for each scale comparing program vs. control scores at end point, adjusted for baseline score
** P-value from Wilcoxon Signed-Rank Test comparing baseline to end point scores (full cohort)